Page 9 - Johnson & Johnson

Do J&J hip implant patients need to pay tax on compensation? Find out here

As the money received is capital receipt, it will be tax-free according to income tax provisions

J&J faulty hip transplant: CIC directs RTI disclosure of crucial documents

A Johnson & Johnson subsidiary caught in a controversy over faulty hip replacement systems has opposed RTI disclosure of crucial documents it submitted to the country's drug regulator for seeking import clearance for these devices, the CIC has said. The commission, however, said it has found no impediment in directing disclosure of these compliance documents. Among the records whose disclosure the DePuy Medical Private Limited, the Johnson and Johnson subsidiary, has opposed was an indemnity clause, said Mukesh Jain, the RTI applicant who had sought the information from Central Drugs Standard Control Organisation (CDSCO). The indemnity clause makes companies liable for compensation to patients globally in case equipment are found faulty. The CDSCO, the drug regulator, did not apply the RTI clause of "larger public interest" to provide the documents, Jain told PTI. Instead, he said, it sought the consent of DePuy Medical Private Limited applying the "third party" clause of the Act

Johnson & Johnson to work with govt for recalled hip implants' compensation

MUMBAI (Reuters) - Johnson & Johnson (J&J) said on Friday it would work with the Indian government to compensate patients who suffered from artificial hip implants the U.S. healthcare company recalled eight years ago.

J&J faulty hip implant case: Govt asks all states to form committees

The government has accepted the proposal but has decided to form state-level committees

Tragic delay

Regulatory oversight of Johnson & Johnson case abysmal

Centre to ask Johnson & Johnson to pay up in hip implants case

The central committee will also consider patients suffering on account of monetary loss due to loss of wages and other losses

J&J hip implant case: Panel recommends per person compensation of Rs 2 mn

Recommends per person compensation of Rs 2 million; changes to rules governing medical devices

Johnson & Johnson vows to appeal $4.7 bn talc verdict awarded to 22 women

J&J says decades of testing by laboratories and independent agencies, including a study by the US Food and Drug Administration, support its position

$4.69 bn verdict against Johnson & Johnson over cancer from talc

Investors are likely to increase their focus on the talc cases on the heels of the large award for the plaintiffs

J&J to pay $550 million after lawsuit links cancer to its baby powder

Nearly two dozen women who claimed asbestos in Johnson & Johnson talcum powder caused their ovarian cancer were awarded USD 550 million in damages by a St Louis jury in the first case against the company that focused on asbestos in the powder. Punitive damages are still to be decided for the 22 plaintiffs in a case that began June 4 in St Louis Circuit Court. Plaintiffs' lawyer Mark Lanier told the jurors during closing arguments on Wednesday that this case was the first where jurors saw documents showing that Johnson & Johnson knew its products contained asbestos and didn't warn consumers, The St. Louis Post-Dispatch reported . "Your voice is not just the voice of the community but the voice of the world," Lanier said. "You don't jack with people's lives like this. ... It's just not right." Johnson & Johnson spokeswoman Carol Goodrich said in a statement that the company was disappointed with yesterday's verdict but would not comment further until the punitive damages are

Investors ready to resuscitate Johnson & Johnson's ailing stock

NEW YORK (Reuters) - Johnson & Johnson shareholders have endured a painful year amid worries about prospects for its many businesses, but investors capitalizing on the stock's relatively cheap valuation may be set to apply a Band-Aid to the declines.

California judge tosses $417 million talc cancer verdict against J&J

(Reuters) - A California judge on Friday threw out a $417 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene.

Johnson & Johnson to pay $417-mn fine

Firm to pay damages to medical receptionist who developed ovarian cancer after using its baby powder

J&J expands portfolio with detergent range for babies

To help the makers of soaps, oils, shampoos, creams and talc for babies fill expand its portfolio

J&J loses $110-million verdict over talc cancer-link claim

There are more than 3,000 lawsuits accusing world's largest health-care company of ignoring studies

Johnson & Johnson told to pay up after powder gives woman ovarian cancer

Thousands of lawsuits have proved that Johnson & Johnsonis primarily a profit oriented company

J&J ordered to pay $110 mn after a woman gets cancer using talc-powder

(Reuters) - Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

J&J wins trial in talc product liability lawsuits

(Reuters) - Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favour in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.

Johnson & Johnson seals $30-billion Actelion deal

Actelion shares surged as much as 22 per cent in Zurich

Johnson & Johnson to buy Swiss biotech firm Actelion for $30 billion

In all-cash deal which includes spinning off Actelion's R&D pipeline